Ibrutinib in the real world patient: many lights and some shades

Abstract

With an estimated incidence of about 4.92 cases per 100,000/year in Europe[1][1] and 14,620 new cases in 2015 in the USA,[2][2] chronic lymphocytic leukemia (CLL) is the most frequent leukemia in Western countries. While a minority of patients may attain long-lasting responses with